| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Comstock Inc.
13D/A
Amendment 2
LODE · 205750409
|
5.2% |
10/16/2026
Event 10/14/2026
|
|||
| MAK Capital Fund LP | 5.2% | ||||
| Mak Capital One LLC | 5.2% | ||||
| Kaufman Michael A | 5.2% | ||||
|
Comstock Inc.
13D/A
Amendment 1
LODE · 205750409
|
6.7% |
9/16/2026
Event 9/14/2026
|
|||
| MAK Capital Fund LP | 6.7% | ||||
| Mak Capital One LLC | 6.7% | ||||
| Kaufman Michael A | 6.7% | ||||
|
Standard BioTools Inc.
13G/A
Amendment 1
LAB · 34385P108
|
6.7% |
5/15/2026
Event 3/31/2026
|
|||
| MAK Capital Fund LP | 6.7% | ||||
| MAK Capital One L.L.C. | 6.7% | ||||
| Michael A. Kaufman | 6.7% | ||||
|
ClearPoint Neuro, Inc.
13G/A
Amendment 1
CLPT · 18507C103
|
6.3% |
5/15/2026
Event 3/31/2026
|
|||
| MAK Capital Fund LP | 6.3% | ||||
| Mak Capital One LLC | 6.3% | ||||
| Kaufman Michael A | 6.3% | ||||
|
Autolus Therapeutics plc
13G/A
Amendment 3
AUTL · 05280R100
|
12.6% |
5/15/2026
Event 3/31/2026
|
|||
| MAK Capital Fund LP | 12.6% | ||||
| Mak Capital One LLC | 12.6% | ||||
| Kaufman Michael A | 12.6% | ||||
|
Evotec SE
13D/A
Amendment 2
EVO · 30050E105
|
7.1% |
5/1/2026
Event 4/29/2026
|
|||
| MAK Capital Fund LP | 7.1% | ||||
| MAK Capital One L.L.C. | 7.1% | ||||
| Michael A. Kaufman | 7.1% | ||||
|
Evotec SE
13D/A
Amendment 1
EVO · 30050E105
|
7.0% |
4/6/2026
Event 4/1/2026
|
|||
| MAK Capital Fund LP | 7.0% | ||||
| MAK Capital One L.L.C. | 7.0% | ||||
| Michael A. Kaufman | 7.0% | ||||
|
Protalix BioTherapeutics, Inc.
13G/A
Amendment 1
PLX · 74365A309
|
4.5% |
3/30/2026
Event 3/24/2026
|
|||
| MAK Capital Fund LP | 4.5% | ||||
| Mak Capital One LLC | 4.5% | ||||
| Kaufman Michael A | 4.5% | ||||
|
Evotec SE
13D
EVO · 30050E105
|
7.0% |
3/30/2026
Event 3/30/2026
|
|||
| MAK Capital Fund LP | 7.0% | ||||
| MAK Capital One L.L.C. | 7.0% | ||||
| Michael A. Kaufman | 7.0% | ||||
|
Comstock Inc.
13D
LODE · 205750409
|
8.1% |
3/25/2026
Event 3/23/2026
|
|||
| MAK Capital Fund LP | 8.1% | ||||
| Mak Capital One LLC | 8.1% | ||||
| Kaufman Michael A | 8.1% | ||||
|
ClearPoint Neuro, Inc.
13G
CLPT · 18507C103
|
6.1% |
3/13/2026
Event 3/10/2026
|
|||
| MAK Capital Fund LP | 6.1% | ||||
| Mak Capital One LLC | 6.1% | ||||
| Kaufman Michael A | 6.1% | ||||
|
Talkspace, Inc.
13G/A
Amendment 1
TALK · 87427V103
|
4.2% |
3/12/2026
Event 3/9/2026
|
|||
| MAK Capital Fund LP | 4.2% | ||||
| MAK Capital One L.L.C. | 4.2% | ||||
| Michael A. Kaufman | 4.2% | ||||
|
Protalix BioTherapeutics, Inc.
13G
PLX · 74365A309
|
5.8% |
3/4/2026
Event 2/26/2026
|
|||
| MAK Capital Fund LP | 5.8% | ||||
| Mak Capital One LLC | 5.8% | ||||
| Kaufman Michael A | 5.8% | ||||
|
Talkspace, Inc.
13G
TALK · 87427V103
|
5.2% |
3/2/2026
Event 2/24/2026
|
|||
| MAK Capital Fund LP | 5.2% | ||||
| MAK Capital One L.L.C. | 5.2% | ||||
| Michael A. Kaufman | 5.2% | ||||
|
Autolus Therapeutics plc
13G/A
Amendment 2
AUTL · 05280R100
|
11.3% |
2/13/2026
Event 12/31/2025
|
|||
| MAK Capital Fund LP | 11.3% | ||||
| MAK Capital One L.L.C. | 11.3% | ||||
| Michael A. Kaufman | 11.3% | ||||
|
DIRTT Environmental Solutions Ltd.
13G/A
Amendment 5
DRTTF · 25490H106
|
4.7% |
2/13/2026
Event 12/31/2025
|
|||
| MAK Capital Fund LP | 4.7% | ||||
| MAK Capital One L.L.C. | 4.7% | ||||
| Michael A. Kaufman | 4.7% | ||||
|
Comstock Inc.
13G
LODE · 205750409
|
7.6%
Checked 5% or less
|
2/5/2026
Event 1/29/2026
|
|||
| MAK Capital Fund LP | 7.6% | ||||
| MAK Capital One L.L.C. | 7.6% | ||||
| Michael A. Kaufman | 7.6% | ||||
|
Evotec SE
13G
EVO · 30050E105
|
5.3% |
1/16/2026
Event 1/9/2026
|
|||
| MAK Capital Fund LP | 5.3% | ||||
| MAK Capital One L.L.C. | 5.3% | ||||
| Michael A. Kaufman | 5.3% | ||||
|
Standard BioTools Inc.
13G
LAB · 34385P108
|
5.2%
Checked 5% or less
|
1/7/2026
Event 12/31/2025
|
|||
| MAK Capital Fund LP | 5.2% | ||||
| MAK Capital One L.L.C. | 5.2% | ||||
| Michael A. Kaufman | 5.2% | ||||
|
Autolus Therapeutics plc
13G/A
Amendment 1
AUTL · 05280R100
|
10.1% |
12/3/2025
Event 12/1/2025
|
|||
| MAK Capital Fund LP | 10.1% | ||||
| MAK Capital One L.L.C. | 10.1% | ||||
| Michael A. Kaufman | 10.1% | ||||
|
Autolus Therapeutics plc
13G
AUTL · 05280R100
|
5.8% |
6/25/2025
Event 6/17/2025
|
|||
| MAK Capital Fund LP | 5.8% | ||||
| MAK Capital One L.L.C. | 5.8% | ||||
| Michael A. Kaufman | 5.8% | ||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.